Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 1/20 | 0.61 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.53 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.53 |
| ▸ | SIGMAR1 | Q99720 | 8/20 | 0.52 |
| ▸ | OPRL1 | P41146 | 3/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.49 |
| ▸ | TSHR | P16473 | 2/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | CCR3 | P51677 | 2/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14387152 | 0.94 | OPRM1 (0.56) | OPRM1CYP3A4HSD17B10SIGMAR1OPRL1 | |
| SCHEMBL4630573 | 0.86 | OPRM1 (0.63) | OPRM1CYP3A4HSD17B10SIGMAR1OPRL1 | |
| SCHEMBL9231786 | 0.84 | OPRM1 (0.61) | OPRM1CYP3A4HSD17B10SIGMAR1OPRL1 | |
| SCHEMBL6636176 | 0.84 | OPRM1 (0.61) | OPRM1CYP3A4HSD17B10SIGMAR1OPRL1 | |
| SCHEMBL14902471 | 0.83 | OPRM1 (0.60) | OPRM1CYP3A4HSD17B10SIGMAR1OPRL1 | |
| SCHEMBL16915778 | 0.82 | OPRM1 (0.58) | OPRM1CYP3A4HSD17B10SIGMAR1OPRL1 | |
| SCHEMBL24093376 | 0.81 | OPRM1 (0.57) | OPRM1CYP3A4HSD17B10SIGMAR1OPRL1 | |
| SCHEMBL18825779 | 0.81 | OPRL1 (0.58) | OPRM1CYP3A4HSD17B10SIGMAR1OPRL1 | |
| SCHEMBL19567416 | 0.81 | OPRM1 (0.57) | OPRM1CYP3A4HSD17B10SIGMAR1OPRL1 | |
| SCHEMBL18319632 | 0.81 | OPRM1 (0.57) | OPRM1CYP3A4HSD17B10SIGMAR1OPRL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119585241-A | AT2R antagonists and uses thereof | 伊莱利利公司 | 2025-03-07 | — | — | CN | disclosed |
| US-20250074875-A1 | AT2R ANTAGONISTS AND USES THEREOF | ELI LILLY AND COMPANY | 2025-03-06 | — | — | US | disclosed |
| US-12122750-B2 | AT2R antagonists and uses thereof | ELI LILLY AND COMPANY (US) | 2024-10-22 | — | — | US | disclosed |
| WO-2023224853-A1 | AT2R ANTAGONISTS AND USES THEREOF | ELI LILLY AND COMPANY (US) | 2023-11-23 | — | — | WO | disclosed |
| WO-2023224853-A1 | AT2R ANTAGONISTS AND USES THEREOF | ELI LILLY AND COMPANY (US) | 2023-11-23 | — | — | WO | disclosed |
| US-20230373919-A1 | AT2R ANTAGONISTS AND USES THEREOF | ELI LILLY AND COMPANY | 2023-11-23 | — | — | US | disclosed |
| US-20230373919-A1 | AT2R ANTAGONISTS AND USES THEREOF | ELI LILLY AND COMPANY | 2023-11-23 | — | — | US | disclosed |
| US-20230373919-A1 | AT2R ANTAGONISTS AND USES THEREOF | ELI LILLY AND COMPANY | 2023-11-23 | — | — | US | disclosed |
| US-20210338849-A1 | COMPOUNDS AND COMPOSITIONS FOR THE DETECTION AND TREATMENT OF ALZHEIMER'S DISEASE AND RELATED DISORDERS | MASSACHUSETTS GEN HOSPITAL (US) | 2021-11-04 | — | — | US | disclosed |
| EP-3231804-B1 | COMPOUNDS AND COMPOSITIONS FOR THE DETECTION AND TREATMENT OF ALZHEIMER'S DISEASE AND RELATED DISORDERS | MASSACHUSETTS GEN HOSPITAL (US) | 2021-03-03 | — | — | EP | disclosed |
| US-7531546-B2 | Spiro-substituted pyrrolo[2,3-D]pyrimidines as cathepsin inhibitors | NOVARTIS AG (CH) | 2009-05-12 | — | — | US | disclosed |
| EP-1592426-B1 | 2-CYANOPYRROLOPYRIMIDINES AND PHARMACEUTICAL USES THEREOF | NOVARTIS AG (CH) | 2007-12-19 | — | — | EP | disclosed |
| US-20060258690-A1 | Spiro-substituted pyrrologyrimidines | NOVARTIS AG (CH) | 2006-11-16 | — | — | US | disclosed |
| US-20060247251-A1 | 2-Cyanopyrrolopyrimidines and pharmaceutical uses thereof | NOVARTIS AG (CH) | 2006-11-02 | — | — | US | disclosed |
| EP-1601677-B1 | SPIRO-SUBSTITUTED PYRROLOPYRIMIDINES | NOVARTIS AG (CH) | 2006-06-28 | — | — | EP | disclosed |
| CN-1756553-A | 2-cyanopyrrolopyrimidines and pharmaceutical uses thereof | NOVARTIS AG (CH) | 2006-04-05 | — | — | CN | disclosed |
| EP-1601677-A1 | SPIRO-SUBSTITUTED PYRROLOPYRIMIDINES | Novartis AG (CH) | 2005-12-07 | — | — | EP | disclosed |
| EP-1592426-A1 | 2-CYANOPYRROLOPYRIMIDINES AND PHARMACEUTICAL USES THEREOF | Novartis AG (CH) | 2005-11-09 | — | — | EP | disclosed |
| WO-2004076455-A1 | SPIRO-SUBSTITUTED PYRROLOPYRIMIDINES | NOVARTIS AG (CH) | 2004-09-10 | — | — | WO | disclosed |
| WO-2004069256-A1 | 2-CYANOPYRROLOPYRIMIDINES AND PHARMACEUTICAL USES THEREOF | NOVARTIS AG (CH) | 2004-08-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060247251-A1 | 2-Cyanopyrrolopyrimidines and pharmaceutical uses thereof | DPYD, P2RY1, P2RY2 | OPRM1 130/4885CYP3A4 840/4885HSD17B10 3710/4885 |
| US-20210338849-A1 | COMPOUNDS AND COMPOSITIONS FOR THE DETECTION AND TREATMENT OF ALZHEIMER'S DISEASE AND RELATED DISORDERS | APP, PSEN1, PSEN2 | OPRM1 4483/4885CYP3A4 3946/4885HSD17B10 2350/4885 |
| US-20230373919-A1 | AT2R ANTAGONISTS AND USES THEREOF | AGTR2, AGTR1, AVPR2 | OPRM1 96/4885CYP3A4 2075/4885HSD17B10 3840/4885 |
| US-20060258690-A1 | Spiro-substituted pyrrologyrimidines | CTSS, CTSK, CTSZ | OPRM1 1399/4885CYP3A4 2356/4885HSD17B10 3754/4885 |
| US-20250074875-A1 | AT2R ANTAGONISTS AND USES THEREOF | AGTR2, AGTR1, AVPR2 | OPRM1 94/4885CYP3A4 2016/4885HSD17B10 3844/4885 |
| US-12122750-B2 | AT2R antagonists and uses thereof | AGTR2, AGTR1, AVPR2 | OPRM1 96/4885CYP3A4 2075/4885HSD17B10 3840/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.